Pharmaceutical Company Commends Advanced of the Year
Release time:
2020-08-14
Pharmaceutical Company Commends Annual Advanced
News 1# July 29 Afternoon, Peak Pharmaceutical Company Held 2017 Annual Summary Commendation Meeting to Summarize the Work of the Past Year, Commend the Outstanding Collectives and Individuals of Pharmaceutical Company 2017 , and Put forward the Work Ideas for the New Year.
2017 is an important year to deepen the reform in an all-round way. The pharmaceutical industry is in a period of policy adjustment and turbulence , . The frequent occurrence of national pharmaceutical policies, especially the continuous promotion of the new medical reform policy and the rapid landing of drug regulatory policies, have brought new opportunities and challenges to the pharmaceutical industry. In the face of the complex and changeable industrial situation and market environment, the pharmaceutical company closely revolves around the business objectives set at the beginning of the year, seizes the opportunity of industry integration and market expansion, carries out all kinds of work in a down-to-earth manner, and achieves good results. On behalf of the management team of the pharmaceutical company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, made a work report entitled "comply with new policies, meet new challenges, gather new forces to achieve new leaps". He made a report on the completion of economic indicators, scientific and technological innovation achievements, brand promotion of enterprises and products, enterprise expansion, completion and use of technological transformation projects, strengthening of internal management and refinement of marketing work, the party-mass work and other aspects reviewed the main work in 2017
2018 . He pointed out that 2018 is a very critical year for the pharmaceutical industry. The newly revised Drug Administration Law will be implemented, and the drug registration management measures, drug technology transfer management measures, drug marketing license holder system, GMP and GSP certification systems will be revised accordingly. With the continuous introduction of policies, the entire industry will undergo tremendous changes. Pharmaceutical companies will proceed from the actual situation of the company, fully tap their own advantages, take innovation and standardization as the main line, and steadily advance various tasks. At the meeting, he made arrangements for the key work of 2018 . Chairman of the Group Company and Chairman of the Pharmaceutical Company Jiang Xiaomeng, Chairman of the Trade Union of the Group Company Qin Xuping and leaders of the Pharmaceutical Company presented awards to the advanced collectives and individuals of the Pharmaceutical Company 2017
2017 respectively. Chairman Jiang Xiaomeng, on behalf of the group company, congratulated the commended advanced collectives and individuals, affirmed the efforts made by all employees of the pharmaceutical company in the past year, and put forward requirements for the work of pharmaceutical company 2018 . He asked pharmaceutical companies to increase talent training; speed up consistency evaluation and new drug research and development; establish the concept of marketing first responsibility, innovate marketing models; expand the scale of retail business; establish and improve internal assessment and incentive mechanisms to mobilize all levels The subjective initiative of personnel. At the
Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page